symbol,synonyms,gene_locus,gene_id,transcript_id,conservation,conservation_ortholog,conservation_species,biological_context,context_detail,tissue/cell line,genome_variation,variation_detail,epigenetic_modification,modification_detail,expression,expression_detail,regulator_type,regulator,regulator_interaction,regulator_effect,target_type,target,target_interaction,target_effect,experimental_method,molecular_function,biological_process,pathway,functional_mechanism,clinical_detail,drug,description,pmid
H19,D11S813E;ASM;ASM1;NCRNA00008;LINC00008;MIR675HG,11p15.5,HSALNG0082178,"HSALNT0171121,HSALNT0171122,HSALNT0171123,HSALNT0171124,HSALNT0171125,HSALNT0289462,HSALNT0361012,HSALNT0361013,HSALNT0361014,HSALNT0361015,HSALNT0361016,HSALNT0361017,HSALNT0361018,HSALNT0361019,HSALNT0361020,HSALNT0361021,HSALNT0361022,HSALNT0361023,HSALNT0361024,HSALNT0361025,HSALNT0361026,HSALNT0361027,HSALNT0361028,HSALNT0361029,HSALNT0361030,HSALNT0361031",,NA,,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR,NA,NA,NA,NA,NA,NA,It may be used in monitoring disease progression and it may serve as potential new targets for novel therapeutic approaches.,27021022
HOTAIR,HOXC-AS4;HOXC11-AS1;NCRNA00072,12q13.13,HSALNG0091318,"HSALNT0189446,HSALNT0189447,HSALNT0189448,HSALNT0289004,HSALNT0368392,HSALNT0368393,HSALNT0368394,HSALNT0368395,HSALNT0368396,HSALNT0368397,HSALNT0368398,HSALNT0368399,HSALNT0368400,HSALNT0368401,HSALNT0368402,HSALNT0368403,HSALNT0368404,HSALNT0368405",,NA,,Disease,parkinson's disease,Midbrain tissue,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,LRRK2,NA,Promote,QRT-PCR;Wetern blotting assay;Mtt assay;RNAi;Q-RCR,NA,Tumorigenesis,NA,NA,NA,NA,"We found that hotair was up-regulated in midbrain tissue of mtpt induced pd mice and in sh-sy5y cells exposed to mpp+.With the presence of hotair overexpression in sh-sy5y cells,the expression of lrrk2 was increased compared with that in the control.The long noncoding rna hotair promotes parkinson's disease by upregulating lrrk2 expression.With the presence of hotair overexpression in sh-sy5y cells,the expression of lrrk2 was increased compared with that in the control.",28445933
HOTAIR,HOXC-AS4;HOXC11-AS1;NCRNA00072,12q13.13,HSALNG0091318,"HSALNT0189446,HSALNT0189447,HSALNT0189448,HSALNT0289004,HSALNT0368392,HSALNT0368393,HSALNT0368394,HSALNT0368395,HSALNT0368396,HSALNT0368397,HSALNT0368398,HSALNT0368399,HSALNT0368400,HSALNT0368401,HSALNT0368402,HSALNT0368403,HSALNT0368404,HSALNT0368405",,NA,,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Q-RCR,NA,NA,NA,NA,NA,NA,Hotair promoted pd induced by mptp through regulating  lrrk2 expression could add our understanding of the molecular mechanisms in pd.,26979073
LINC00319,PRED49;FLJ38036;C21orf125;NCRNA00319,21q22.3,HSALNG0133418,"HSALNT0274241,HSALNT0274245,HSALNT0274256,HSALNT0274270,HSALNT0274271,HSALNT0274272,HSALNT0404462,HSALNT0404463,HSALNT0404464,HSALNT0404465,HSALNT0404466,HSALNT0404467,HSALNT0404468,HSALNT0404469,HSALNT0404470",,NA,,Disease,parkinson's disease,NA,NA,NA,DNA methylation,cg01820192,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28851441
LINC00908,ASRPS,18q23,,,,NA,,Disease,parkinson's disease,NA,NA,NA,DNA methylation,cg16270399,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28851441
LINC01262,TCONS_l2_00021807;RP11-462G22.1,4q35.2,HSALNG0039360,"HSALNT0082787,HSALNT0082788,HSALNT0289102,HSALNT0324569,HSALNT0324570",,NA,,Disease,parkinson's disease,Blood,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR;Rna sequencing,NA,NA,NA,NA,NA,NA,"Differentially expressed lncRNAs in pd leukocytes compared to hc.Among all the leukocyte rna-seq detected lncRNAs,13 exhibited differential expression in pd patients compared to matched control volunteers (fdr<0.05).Of these,8 exhibited disease-mediated decrease,and 5-increase.These included the u1 spliceosomal lncRNA and rp11-462g22.1,each entailing sequence complementarity to numerous micrornas.",24651478
LINC01734,,20q12,HSALNG0130047,"HSALNT0267102,HSALNT0401013",,NA,,Disease,parkinson's disease,Blood,NA,NA,NA,NA,RNA,Down-regulated,NA,NA,NA,NA,NA,NA,NA,NA,Rna sequencing,NA,NA,NA,NA,NA,NA,"Differentially expressed lncRNAs in pd leukocytes compared to hc.Among all the leukocyte rna-seq detected lncRNAs,13 exhibited differential expression in pd patients compared to matched control volunteers (fdr<0.05).Of these,8 exhibited disease-mediated decrease,and 5-increase.",24651478
MALAT1,PRO1073;MALAT-1;NCRNA00047;HCN;NEAT2;LINC00047;mascRNA,11q13.1,HSALNG0084905,"HSALNT0176789,HSALNT0176790,HSALNT0176796,HSALNT0176798,HSALNT0176802,HSALNT0176803,HSALNT0176804,HSALNT0176807,HSALNT0176808,HSALNT0176810,HSALNT0176813,HSALNT0176815,HSALNT0176817,HSALNT0176818,HSALNT0176819,HSALNT0176821,HSALNT0176823,HSALNT0176825,HSALNT0176826,HSALNT0176827,HSALNT0176830,HSALNT0176832,HSALNT0176833,HSALNT0176835,HSALNT0176837,HSALNT0176838,HSALNT0289363,HSALNT0363299,HSALNT0363300,HSALNT0363301,HSALNT0363302,HSALNT0363303,HSALNT0363304,HSALNT0363305,HSALNT0363306,HSALNT0363307,HSALNT0363308,HSALNT0363309,HSALNT0363310,HSALNT0363311,HSALNT0363312,HSALNT0363313,HSALNT0363315,HSALNT0363316,HSALNT0363317,HSALNT0363318,HSALNT0363319,HSALNT0363320,HSALNT0363321,HSALNT0363322,HSALNT0363323,HSALNT0363324,HSALNT0363325",Y,NA,Mammal,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR;Q-RCR;Wetern blotting assay,NA,NA,NA,NA,NA,NA,It may be used in monitoring disease progression and it may serve as potential new targets for novel therapeutic approaches.,27021022
MALAT1,PRO1073;MALAT-1;NCRNA00047;HCN;NEAT2;LINC00047;mascRNA,11q13.1,HSALNG0084905,"HSALNT0176789,HSALNT0176790,HSALNT0176796,HSALNT0176798,HSALNT0176802,HSALNT0176803,HSALNT0176804,HSALNT0176807,HSALNT0176808,HSALNT0176810,HSALNT0176813,HSALNT0176815,HSALNT0176817,HSALNT0176818,HSALNT0176819,HSALNT0176821,HSALNT0176823,HSALNT0176825,HSALNT0176826,HSALNT0176827,HSALNT0176830,HSALNT0176832,HSALNT0176833,HSALNT0176835,HSALNT0176837,HSALNT0176838,HSALNT0289363,HSALNT0363299,HSALNT0363300,HSALNT0363301,HSALNT0363302,HSALNT0363303,HSALNT0363304,HSALNT0363305,HSALNT0363306,HSALNT0363307,HSALNT0363308,HSALNT0363309,HSALNT0363310,HSALNT0363311,HSALNT0363312,HSALNT0363313,HSALNT0363315,HSALNT0363316,HSALNT0363317,HSALNT0363318,HSALNT0363319,HSALNT0363320,HSALNT0363321,HSALNT0363322,HSALNT0363323,HSALNT0363324,HSALNT0363325",Y,NA,Mammal,Disease,parkinson's disease,Bone;Sy5y,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,alpha-synuclein,NA,NA,QRT-PCR;Q-RCR;Wetern blotting assay,NA,NA,NA,NA,NA,NA,"Rna pull-down and immunoprecipitation assays confirmed that malat1 associated with 伭synuclein,leading to the increased stability of 伭synuclein and its expression in sh-sy5y cells.βasarone functions as a neuroprotective effect in both in vivo and in vitro models of pd via regulating malat1 and 伭synuclein expression.",27470562
MALAT1,PRO1073;MALAT-1;NCRNA00047;HCN;NEAT2;LINC00047;mascRNA,11q13.1,HSALNG0084905,"HSALNT0176789,HSALNT0176790,HSALNT0176796,HSALNT0176798,HSALNT0176802,HSALNT0176803,HSALNT0176804,HSALNT0176807,HSALNT0176808,HSALNT0176810,HSALNT0176813,HSALNT0176815,HSALNT0176817,HSALNT0176818,HSALNT0176819,HSALNT0176821,HSALNT0176823,HSALNT0176825,HSALNT0176826,HSALNT0176827,HSALNT0176830,HSALNT0176832,HSALNT0176833,HSALNT0176835,HSALNT0176837,HSALNT0176838,HSALNT0289363,HSALNT0363299,HSALNT0363300,HSALNT0363301,HSALNT0363302,HSALNT0363303,HSALNT0363304,HSALNT0363305,HSALNT0363306,HSALNT0363307,HSALNT0363308,HSALNT0363309,HSALNT0363310,HSALNT0363311,HSALNT0363312,HSALNT0363313,HSALNT0363315,HSALNT0363316,HSALNT0363317,HSALNT0363318,HSALNT0363319,HSALNT0363320,HSALNT0363321,HSALNT0363322,HSALNT0363323,HSALNT0363324,HSALNT0363325",Y,NA,Mammal,Disease,parkinson's disease,Stomach;Mn9d,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,miRNA,miR-205-5p,RNA-RNA,NA,NA,NA,NA,NA,NA,NA,NA,"The malat1/mir-205-5p axis regulates mpp+-induced apoptosis in mn9d cells by targeting lrrk2,thereby improving our understanding of the molecular pathogenesis of pd.",29511451
MAPT-AS1,,17q21.31,HSALNG0141638,HSALNT0289365,,NA,,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Genotyping,NA,NA,NA,NA,NA,NA,"Increased mapt expression could be associated with disease state,but not with pd neuropathology severity.",27336847
MIR4422HG,RP11-101C11.1,1p32.3,HSALNG0003824,"HSALNT0007121,HSALNT0007122,HSALNT0007123,HSALNT0007125,HSALNT0007127,HSALNT0007128,HSALNT0007129,HSALNT0007130,HSALNT0007138,HSALNT0007139,HSALNT0292302,HSALNT0292303",,NA,,Disease,parkinson's disease,Blood,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,NA,NA,NA,NA,Rna sequencing,NA,NA,NA,NA,NA,NA,"Differentially expressed lncRNAs in pd leukocytes compared to hc.Among all the leukocyte rna-seq detected lncRNAs,13 exhibited differential expression in pd patients compared to matched control volunteers (fdr<0.05).Of these,8 exhibited disease-mediated decrease,and 5-increase.",24651478
NEAT1,TncRNA;MENepsilon/beta;LINC00084;VINC;NCRNA00084,11q13.1,HSALNG0084892,"HSALNT0176751,HSALNT0176753,HSALNT0176757,HSALNT0176758,HSALNT0176759,HSALNT0176762,HSALNT0176765,HSALNT0289192,HSALNT0363258,HSALNT0363259,HSALNT0363260,HSALNT0363261,HSALNT0363262,HSALNT0363263,HSALNT0363264,HSALNT0363265,HSALNT0363266,HSALNT0363267,HSALNT0363268,HSALNT0363269,HSALNT0363270,HSALNT0363271,HSALNT0363272,HSALNT0363273,HSALNT0363274,HSALNT0363275,HSALNT0363276,HSALNT0363277,HSALNT0363278,HSALNT0363279,HSALNT0363280,HSALNT0363281,HSALNT0363282,HSALNT0363283,HSALNT0363284,HSALNT0363285,HSALNT0363286,HSALNT0363287,HSALNT0363289",Y,NA,Placental mammal,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR,NA,NA,NA,NA,NA,NA,It may be used in monitoring disease progression and it may serve as potential new targets for novel therapeutic approaches.,27021022
NEAT1,TncRNA;MENepsilon/beta;LINC00084;VINC;NCRNA00084,11q13.1,HSALNG0084892,"HSALNT0176751,HSALNT0176753,HSALNT0176757,HSALNT0176758,HSALNT0176759,HSALNT0176762,HSALNT0176765,HSALNT0289192,HSALNT0363258,HSALNT0363259,HSALNT0363260,HSALNT0363261,HSALNT0363262,HSALNT0363263,HSALNT0363264,HSALNT0363265,HSALNT0363266,HSALNT0363267,HSALNT0363268,HSALNT0363269,HSALNT0363270,HSALNT0363271,HSALNT0363272,HSALNT0363273,HSALNT0363274,HSALNT0363275,HSALNT0363276,HSALNT0363277,HSALNT0363278,HSALNT0363279,HSALNT0363280,HSALNT0363281,HSALNT0363282,HSALNT0363283,HSALNT0363284,HSALNT0363285,HSALNT0363286,HSALNT0363287,HSALNT0363289",Y,NA,Placental mammal,Disease,parkinson's disease,Sy5y,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR,NA,NA,NA,NA,NA,NA,"Up-regulated neat1 was found in mptp-induced pd mice.Moreover,the neat1 expression was positively correlated with the concentration of mpp+.In sh-sy5y cells stimulated by mpp+,neat1 knockdown dramatically promoted cell viability and suppressed cell apoptosis.Additionally,down-regulation of neat1 also decreased the ratio of bax/bcl-2,the activity of caspase-3,as well as the expression of 伭synuclein.Moreover,伭synuclein overexpression could significantly reverse the increase in cell viability and the decrease in cell apoptosis induced by neat1 knockdown.",29575151
PCA3,DD3;NCRNA00019;PCAT3;PRUNE2-AS1,9q21.2,HSALNG0072040,"HSALNT0150560,HSALNT0150561,HSALNT0150562,HSALNT0150563,HSALNT0150565,HSALNT0150566,HSALNT0150567,HSALNT0150568,HSALNT0150569,HSALNT0150570,HSALNT0150571,HSALNT0150572,HSALNT0150573,HSALNT0150574,HSALNT0289203,HSALNT0352926,HSALNT0352927,HSALNT0352928,HSALNT0352929,HSALNT0352930,HSALNT0352931,HSALNT0352932,HSALNT0352933,HSALNT0352934,HSALNT0352935,HSALNT0352936,HSALNT0352937,HSALNT0352938,HSALNT0352939,HSALNT0352940,HSALNT0352941,HSALNT0352942,HSALNT0352943,HSALNT0352944,HSALNT0352945,HSALNT0352946,HSALNT0352947,HSALNT0352948,HSALNT0352949,HSALNT0352950,HSALNT0352951",,NA,,Disease,parkinson's disease,Blood,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,NA,NA,NA,NA,Rna sequencing,NA,NA,NA,NA,NA,NA,"Differentially expressed lncRNAs in pd leukocytes compared to hc.Among all the leukocyte rna-seq detected lncRNAs,13 exhibited differential expression in pd patients compared to matched control volunteers (fdr<0.05).Of these,8 exhibited disease-mediated decrease,and 5-increase.",24651478
PIK3CD-AS1,C1orf200,1p36.22,HSALNG0142109,HSALNT0290212,,NA,,Disease,parkinson's disease,NA,NA,NA,DNA methylation,cg11334709,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,,28851441
PINK1-AS,FLJ00387;PINK1AS;naPINK1;PINK1-AS1,1p36.12,HSALNG0001461,"HSALNT0002762,HSALNT0289387,HSALNT0290648",,NA,,Disease,parkinson's disease,Neuronal,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Q-RCR,NA,NA,NA,NA,NA,NA,Mutations in the pten induced putative kinase 1 (pink1) are implicated in early-onset parkinson's disease.Naturally occurring non-coding antisense provides sophisticated mechanisms for diversifying genomes and wedescribe a human specific non-coding antisense expressed at the pink1 locus (napink1).,17362513
SCOC-AS1,,4q31.1,HSALNG0037485,"HSALNT0078565,HSALNT0078566,HSALNT0078567,HSALNT0078568,HSALNT0078570,HSALNT0078573,HSALNT0078574,HSALNT0078577,HSALNT0078578,HSALNT0322561,HSALNT0322562,HSALNT0322563,HSALNT0322564,HSALNT0322565,HSALNT0322566,HSALNT0322567,HSALNT0322568,HSALNT0322569,HSALNT0322570,HSALNT0322571,HSALNT0322572,HSALNT0322575,HSALNT0322576,HSALNT0322577",,NA,,Disease,parkinson's disease,Blood,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,NA,NA,NA,NA,Rna sequencing,NA,NA,NA,NA,NA,NA,"Differentially expressed lncRNAs in pd leukocytes compared to hc.Among all the leukocyte rna-seq detected lncRNAs,13 exhibited differential expression in pd patients compared to matched control volunteers (fdr<0.05).Of these,8 exhibited disease-mediated decrease,and 5-increase.",24651478
SNHG1,UHG;NCRNA00057;LINC00057;lncRNA16,11q12.3,HSALNG0084672,"HSALNT0176321,HSALNT0176322,HSALNT0176323,HSALNT0176324,HSALNT0176326,HSALNT0176328,HSALNT0176338,HSALNT0176341,HSALNT0176342,HSALNT0176343,HSALNT0176344,HSALNT0176345,HSALNT0176349,HSALNT0176350,HSALNT0176351,HSALNT0176352,HSALNT0176353,HSALNT0176355,HSALNT0176356,HSALNT0176357,HSALNT0176358,HSALNT0176360,HSALNT0176364,HSALNT0176365,HSALNT0176373,HSALNT0176376,HSALNT0176381,HSALNT0176391,HSALNT0176401,HSALNT0363079,HSALNT0363080,HSALNT0363081,HSALNT0363082,HSALNT0363083,HSALNT0363084,HSALNT0363085,HSALNT0363086,HSALNT0363087,HSALNT0363088,HSALNT0363089,HSALNT0363090,HSALNT0363091,HSALNT0363092,HSALNT0363093,HSALNT0363094,HSALNT0363095,HSALNT0363096,HSALNT0363097,HSALNT0363098,HSALNT0363099,HSALNT0363100,HSALNT0363101,HSALNT0363102,HSALNT0363103,HSALNT0363104,HSALNT0363105,HSALNT0363106,HSALNT0363107,HSALNT0363108,HSALNT0363109,HSALNT0363110,HSALNT0363111,HSALNT0363112,HSALNT0363113,HSALNT0363114,HSALNT0363115,HSALNT0363116,HSALNT0363117,HSALNT0363118,HSALNT0363119,HSALNT0363120,HSALNT0363121,HSALNT0363122,HSALNT0363123,HSALNT0363124,HSALNT0363125,HSALNT0363126,HSALNT0363127,HSALNT0363128,HSALNT0363129,HSALNT0363130,HSALNT0363131,HSALNT0363132,HSALNT0363133,HSALNT0363134,HSALNT0363135,HSALNT0363136",,NA,,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,QRT-PCR,NA,NA,NA,NA,NA,NA,It may be used in monitoring disease progression and it may serve as potential new targets for novel therapeutic approaches.,27021022
SNHG1,UHG;NCRNA00057;LINC00057;lncRNA16,11q12.3,HSALNG0084672,"HSALNT0176321,HSALNT0176322,HSALNT0176323,HSALNT0176324,HSALNT0176326,HSALNT0176328,HSALNT0176338,HSALNT0176341,HSALNT0176342,HSALNT0176343,HSALNT0176344,HSALNT0176345,HSALNT0176349,HSALNT0176350,HSALNT0176351,HSALNT0176352,HSALNT0176353,HSALNT0176355,HSALNT0176356,HSALNT0176357,HSALNT0176358,HSALNT0176360,HSALNT0176364,HSALNT0176365,HSALNT0176373,HSALNT0176376,HSALNT0176381,HSALNT0176391,HSALNT0176401,HSALNT0363079,HSALNT0363080,HSALNT0363081,HSALNT0363082,HSALNT0363083,HSALNT0363084,HSALNT0363085,HSALNT0363086,HSALNT0363087,HSALNT0363088,HSALNT0363089,HSALNT0363090,HSALNT0363091,HSALNT0363092,HSALNT0363093,HSALNT0363094,HSALNT0363095,HSALNT0363096,HSALNT0363097,HSALNT0363098,HSALNT0363099,HSALNT0363100,HSALNT0363101,HSALNT0363102,HSALNT0363103,HSALNT0363104,HSALNT0363105,HSALNT0363106,HSALNT0363107,HSALNT0363108,HSALNT0363109,HSALNT0363110,HSALNT0363111,HSALNT0363112,HSALNT0363113,HSALNT0363114,HSALNT0363115,HSALNT0363116,HSALNT0363117,HSALNT0363118,HSALNT0363119,HSALNT0363120,HSALNT0363121,HSALNT0363122,HSALNT0363123,HSALNT0363124,HSALNT0363125,HSALNT0363126,HSALNT0363127,HSALNT0363128,HSALNT0363129,HSALNT0363130,HSALNT0363131,HSALNT0363132,HSALNT0363133,HSALNT0363134,HSALNT0363135,HSALNT0363136",,NA,,Disease,parkinson's disease,Sy5y,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG,SIAH1,NA,Promote,Bioinformatic analysis;Luciferase reporter gene assay;Q-RCR;Luciferase reporter assay,NA,Evading apoptosis;Cytotoxicity;Apoptosis,NA,ceRNA,NA,NA,"LncRNA snhg1 promotes alpha-synuclein aggregation and toxicity by targeting mir-15b-5p to activate siah1 in human neuroblastoma sh-sy5y cells/in this study,We found that lncRNA small nucleolar rna host gene 1 (snhg1) and seven in absentia homolog 1 (siah1) were upregulated,but microrna-15b-5p (mir-15b-5p) was downregulated in sh-sy5y cells pretreated with mpp+,as well as in mptp-induced mouse model of pd.Overexpression of siah1 enhanced cellular toxicity of 伭synuclein in sh-sy5y cells,as indicated by the reduction of cell viability and elevation of ldh release.The percentage of 伭synuclein aggregate-positive cells and the number of 伭synuclein aggregates per cell were increased in sh-sy5y cells transfected with pcdna-siah1,while decreased after transfection with short interfering rna specific for siah1 (si-siah1).Bioinformatics and luciferase reporter assay revealed that siah1 was a direct target of mir-15b-5p.We also found that snhg1 could directly bind to mir-15-5p and repress mir-15-5p expression.Upregulation of mir-15b-5p alleviated 伭synuclein aggregation and apoptosis by targeting siah1 in sh-sy5y cells overexpressing 伭synuclein.Overexpression of snhg1 enhanced,whereas snhg1 knockdown inhibited 伭synuclein aggregation and 伭synuclein-induced apoptosis.Moreover,the neuroprotective effect of si-snhg1 was abrogated by downregulation of mir-15b-5p.",29217406
SNHG1,UHG;NCRNA00057;LINC00057;lncRNA16,11q12.3,HSALNG0084672,"HSALNT0176321,HSALNT0176322,HSALNT0176323,HSALNT0176324,HSALNT0176326,HSALNT0176328,HSALNT0176338,HSALNT0176341,HSALNT0176342,HSALNT0176343,HSALNT0176344,HSALNT0176345,HSALNT0176349,HSALNT0176350,HSALNT0176351,HSALNT0176352,HSALNT0176353,HSALNT0176355,HSALNT0176356,HSALNT0176357,HSALNT0176358,HSALNT0176360,HSALNT0176364,HSALNT0176365,HSALNT0176373,HSALNT0176376,HSALNT0176381,HSALNT0176391,HSALNT0176401,HSALNT0363079,HSALNT0363080,HSALNT0363081,HSALNT0363082,HSALNT0363083,HSALNT0363084,HSALNT0363085,HSALNT0363086,HSALNT0363087,HSALNT0363088,HSALNT0363089,HSALNT0363090,HSALNT0363091,HSALNT0363092,HSALNT0363093,HSALNT0363094,HSALNT0363095,HSALNT0363096,HSALNT0363097,HSALNT0363098,HSALNT0363099,HSALNT0363100,HSALNT0363101,HSALNT0363102,HSALNT0363103,HSALNT0363104,HSALNT0363105,HSALNT0363106,HSALNT0363107,HSALNT0363108,HSALNT0363109,HSALNT0363110,HSALNT0363111,HSALNT0363112,HSALNT0363113,HSALNT0363114,HSALNT0363115,HSALNT0363116,HSALNT0363117,HSALNT0363118,HSALNT0363119,HSALNT0363120,HSALNT0363121,HSALNT0363122,HSALNT0363123,HSALNT0363124,HSALNT0363125,HSALNT0363126,HSALNT0363127,HSALNT0363128,HSALNT0363129,HSALNT0363130,HSALNT0363131,HSALNT0363132,HSALNT0363133,HSALNT0363134,HSALNT0363135,HSALNT0363136",,NA,,Disease,parkinson's disease,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,PCG;miRNA,GSK3B;miR-15b-5p,NA;NA,promote;inhibit,QRT-PCR;Luciferase reporter assay,NA,Cytotoxicity,NA,ceRNA,NA,NA,"Upregulated lncRNA small nucleolar rna host gene 1 promotes 1-methyl-4-phenylpyridinium ion-induced cytotoxicity and reactive oxygen species production through mir-15b-5p/gsk3beta axis in human dopaminergic sh-sy5y cells.Snhg1 was demonstrated to interact with mir-15b-5p.Moreover,snhg1 could attenuate the inhibitory effects of mir-15b-5p on mpp+ -induced cytotoxicity and production of ros.The inhibitory effects of snhg1 knockdown or mir-15b-5p overexpression on mpp+ -induced cytotoxicity and reactive oxygen species (ros) production were abrogated by upregulation of gsk3beta.Gsk3betais a target gene of mir-15b-5p.",30302821
SNHG10,,,,,,NA,,Disease,Parkinson’s disease,SH-SY5Y,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-1277-5p,RNA-RNA,Inhibit,Dual luciferase reporter assay,NA,Apoptosis;Proliferation,NA,ceRNA,NA,NA,,34967697
FAM201A,C9orf122,9p13.1,HSALNG0071146,,,NA,,Disease,Parkinsons disease,NA,NA,NA,NA,NA,RNA,Down-regulated,NA,NA,NA,NA,miRNA,miR‑146a‑5p,RNA-RNA,Inhibit,NA,NA,Apoptosis,NA,ceRNA,NA,NA,,34796909
LINC00667,,,,,,NA,,Disease,Parkinsons disease,SH-SY5Y,NA,NA,NA,NA,NA,NA,Protein,HNF4A,Protein-DNA,Promote,miRNA,miR-34c-5p,RNA-RNA,Inhibit,NA,aggravate neuronal injury,Cell viability,NA,ceRNA,1-methyl-4-phenylpyridinium,drug,,35426258
LINC00938,,,,,,NA,,Disease,Parkinsons Disease,Blood;HEK293T,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,hsa-miR-30c-5p,RNA-RNA,Inhibit,Dual luciferase reporter assay,NA,NA,NA,ceRNA,NA,NA,,35173238
MEG3,GTL2;LINC00023;NCRNA00023;onco-lncRNA-83,14q32.2,,,,NA,,Disease,Parkinsons disease,NA,NA,NA,NA,NA,RNA,Down-regulated,NA,NA,NA,NA,PCG,LRRK2,Protein-RNA,Promote,NA,NA,Apoptosis,NA,NA,NA,NA,,34643842
MIR17HG,,,,,,NA,,Disease,Parkinsons disease,blood;SH-SY5Y;BV2,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-153-3p,RNA-RNA,Inhibit,Dual luciferase reporter assay,NA,Apoptosis;Inflammatory response,NA,ceRNA,NA,NA,,35137671
OIP5-AS1,cyrano;linc-OIP5,15q15.1,HSALNG0105343,,,NA,,Disease,Parkinsons disease,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-137,RNA-RNA,Inhibit,Dual luciferase reporter assay,NA,NA,NA,ceRNA,NA,NA,,35049152
SNHG12,PNAS-123;LINC00100;ASLNC04080;C1orf79,1p35.3,HSALNG0002075,,,NA,,Disease,Parkinsons disease,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,miRNA,miR-138-5p,RNA-RNA,Inhibit,NA,NA,Apoptosis,NA,ceRNA,NA,NA,,34783303
ANRIL,CDKN2B-AS1;CDKN2BAS;NCRNA00089;PCAT12;p15AS;RP11-145E5.4;CDKN2B-AS,,,,,NA,,Disease,Parkinson,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR-125a,RNA-RNA,Inhibit,NA,NA,NA,NA,ceRNA,NA,NA,,34921567
LncZFAS1,,,,,,NA,,Disease,Parkinson,NA,NA,NA,NA,NA,RNA,Up-regulated,NA,NA,NA,NA,miRNA,miR590-3p,RNA-RNA,Inhibit,NA,NA,Cancer proliferation,NA,ceRNA,NA,NA,,34775541
